Generation Bio Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Generation Bio şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.2%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.2%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Apr 20

Generation Bio: High-Risk, Medium-To-Low-Reward

Dec 30

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Nov 11

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Jul 28

Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Mar 08

Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Jan 14

Generation Bio's insiders on buying spree, stock +4%

Jan 13

Generation Bio prices equity offering at $24.50

Jan 07

Generation Bio files to offer 7.5M shares

Jan 04

Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

Dec 27

Generation Bio EPS misses by $0.01

Nov 10

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: GBIO şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: GBIO şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Generation Bio Piyasaya Karşı Temettü Getirisi

GBIO temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (GBIO)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (GBIO) (3 yıla kadar)	n/a

Önemli Temettü: GBIO şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, GBIO şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: GBIO şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: GBIO herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Generation Bio Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

New minor risk - Market cap size

Consensus revenue estimates increase by 50%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 38%, EPS downgraded

Generation Bio Co. has filed a Follow-on Equity Offering in the amount of $237 million.

Consensus revenue estimates increase by 29%, EPS downgraded

Generation Bio Co. Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms At the ASGCT 27th Annual Meeting

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Generation Bio Co., Annual General Meeting, Jun 06, 2024

Insufficient new directors

Consensus revenue estimates increase by 101%

Price target decreased by 16% to US$7.25

New major risk - Revenue and earnings growth

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Independent Director recently bought US$478k worth of stock

Generation Bio Co. Announces Termination of Executives, Effective on January 28, 2024

Consensus revenue estimates increase by 51%

Price target decreased by 17% to US$9.00

Generation Bio Co. Announces Demonstration of Highly Selective T Cell Transduction in Vivo with Cell-Targeted Lnp Platform

New minor risk - Market cap size

Generation Bio Co. Announces Breakthrough in Its Non-Viral Genetic Medicine Platform with Novel "Immune-Quiet" Dna

Consensus revenue estimates increase by 270%

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target decreased by 12% to US$11.42

New major risk - Share price stability

Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Price target decreased by 19% to US$13.00

Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$16.67

Insufficient new directors

Price target decreased to US$16.67

President exercised options and sold US$58k worth of stock

Generation Bio Co. Names Phillip Samayoa as Chief Strategy Officer

Independent Director recently bought US$127k worth of stock

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Generation Bio GAAP EPS of -$0.66 misses by $0.04

Insufficient new directors

Generation Bio Co. Appoints Dannielle Appelhans as Class III Director and Member of N&G Committee

Generation Bio Co.(NasdaqGS:GBIO) dropped from Russell 2000 Growth Index

Generation Bio Co. Announces Update to its Good Manufacturing Process Manufacturing Strategy

Price target decreased to US$20.40

Insufficient new directors

Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Price target decreased to US$20.40

Generation Bio Co. Appoints Antoinette Paone as Chief Operating Officer

Generation Bio: High-Risk, Medium-To-Low-Reward

Generation Bio Provides Update on Preclinical Studies for Hemophilia A Program

Price target decreased to US$33.40

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Insufficient new directors

Chief Scientific Officer exercised options and sold US$64k worth of stock

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update

Chief Medical Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$136k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$269k worth of stock

Chief Development Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$96k worth of stock

Chief Medical Officer exercised options and sold US$351k worth of stock

Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

President notifies of intention to sell stock

Generation Bio Co. Appoints Ron Cooper to its Board of Directors, Effective March 1, 2021

Co-Founder & COO Mark Angelino has left the company

Chief Development Officer exercised options and sold US$71k worth of stock

Chief Medical Officer notifies of intention to sell stock

Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Generation Bio's insiders on buying spree, stock +4%

Generation Bio prices equity offering at $24.50

Generation Bio Announces Two Non-Viral Gene Therapy Achievements: Target Levels of Factor VIII Expression in Hemophilia A Mice and Translation of Expression from Mice to Non-Human Primates

Generation Bio files to offer 7.5M shares

Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

Chief Scientific Officer notifies of intention to sell stock

New 90-day high: US$32.04